





VENABLE | Fitzpatrick


September 30, 2020











FWD = Final Written Decision



Spotlight On: Pegfilgrastim

September 30, 2020

Technology: Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It stimulates bone marrow to produce neutrophils (a type of white blood cell) to fight infection.

	Amgen v. Apotex 0:15-cv-61631 (S.D. Fla.) '784 Patent settled, '138 Patent not infringed, not unenforceable, invalidity dismissed Fed. Cir. 17-1010 Affirmed	Sá 2:16- (D (E dec judgn infrin inval Volt	ngen v. andoz cv-01276 J.N.J.) BPCIA laratory nent suit, gement / idity not leged) untarily missed	Amgen v. Sandoz 3:16-cv-02581 (N.D. Cal.) Summary judgment of non- infringement; Fed. Cir. 18-1552 Affirmed, Petition for en banc rehearing granted-in-part, denied-in-part	Amgen v. Apotex 0:18-cv-61828 (S.D. Fla.) Stipulated dismissal	Fe Fv rer	PR2016-01542 WD (All claims npatentable on request for rehearing); ed. Cir. 19-2171 Vacated and manded due to Arthrex; o. Ct. 20-74 Writertiorari pending	IPF Se	Kashiv OSciences v. Amgen 12019-00791 ettled after nstitution	Fresenius Kabi v. Amgen IPR2019-00971 Institution denied		Fresenius Kabi v. Amgen IPR2020-00314 Settled prior to institution decision
5,824,784	Х		Χ	Х								
8,940,878			Х	X					Х			
8,952,138	X					Х						
9,856,287					x					X		X
	Amgen v. Coherus 1:17-cv-00546 (D. Del.) Dismissed for failure to state a claim; Fed. Cir. 18-1993 Affirmed		Amgen v. Mylan 2:17-cv-01235 (W.D. Pa.) '997 Patent stipulation of non-infringement, '707 Patent judgment of non-infringement		Sandoz v. Amgen 3:19-cv-00977 (N.D. Cal.) Voluntarily dismissed		Amgen v. Hospira 1:20-cv-00201 (D. Del.) Ongoing		Kashiv BioSciences v. Amgen IPR2019-00797 Settled after institution		Fresenius Kabi v. Amgen IPR2019-01183 Settled after institution	
8,273,707	Х		X				Χ					
9,643,997				Х	х				Х			X